Eli Lilly bets $2.8bn on AtaiBeckley’s psychedelic therapies for depression European Pharmaceutical Review 4d
Lonza delivered strong H1 2026 performance across all business platforms and upgrades full-year 2026 margin outlook Manufacturing Chemist 14h
An FDA committee just voted in favor of peptides—despite the agency's opposition TIME 1d FDA Inflammatory Bowel Disease US
Why Is Novo Nordisk Suing Eli Lilly, and What Does it Mean for Investors? The Motley Fool 9h Amycretin Novo Nordisk Pharma All sources
Eli Lilly’s retatrutide hits Phase III goals with FDA filing planned for 2027 Manufacturing Chemist 12h Obesity FDA Pharma All sources
Eli Lilly-backed Scribe Therapeutics climbs 67% after raising $128.7 million in an upsized IPO Mint 9h Viking Therapeutics Flotations/IPOs Pharma All sources
With a little help from pharma friends: Psychedelics for psychiatric therapy The Economic Times 8h Pharma Biotechnology
